FR2775189B1 - ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES - Google Patents

ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES

Info

Publication number
FR2775189B1
FR2775189B1 FR9809470A FR9809470A FR2775189B1 FR 2775189 B1 FR2775189 B1 FR 2775189B1 FR 9809470 A FR9809470 A FR 9809470A FR 9809470 A FR9809470 A FR 9809470A FR 2775189 B1 FR2775189 B1 FR 2775189B1
Authority
FR
France
Prior art keywords
hla
antigens
antibodies
compositions based
tumor compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9809470A
Other languages
French (fr)
Other versions
FR2775189A1 (en
Inventor
Edgardo Delfino Carosella
Jean Dausset
Philippe Moreau
Pascale Paul
Freiss Nathalie Rouas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9809470A priority Critical patent/FR2775189B1/en
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to DE69918413T priority patent/DE69918413T2/en
Priority to EP99904919A priority patent/EP1054688B1/en
Priority to CA002321222A priority patent/CA2321222A1/en
Priority to ES99904919T priority patent/ES2224603T3/en
Priority to JP2000532142A priority patent/JP4470007B2/en
Priority to US09/622,583 priority patent/US6790638B1/en
Priority to PCT/FR1999/000386 priority patent/WO1999042128A1/en
Publication of FR2775189A1 publication Critical patent/FR2775189A1/en
Application granted granted Critical
Publication of FR2775189B1 publication Critical patent/FR2775189B1/en
Priority to US10/788,374 priority patent/US20040209296A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR9809470A 1998-02-20 1998-07-24 ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES Expired - Fee Related FR2775189B1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9809470A FR2775189B1 (en) 1998-07-24 1998-07-24 ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES
EP99904919A EP1054688B1 (en) 1998-02-20 1999-02-19 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses
CA002321222A CA2321222A1 (en) 1998-02-20 1999-02-19 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses
ES99904919T ES2224603T3 (en) 1998-02-20 1999-02-19 PROCEDURE FOR SELECTION OF TUMORS THAT EXPRESS HLA-G SENSITIVE TO ANTI-TARGET TREATMENT AND ITS APPLICATIONS.
DE69918413T DE69918413T2 (en) 1998-02-20 1999-02-19 SELECTION PROCEDURE OF HLA-G EXPRESSIVE TUMORS THAT ARE TREATABLE BY ANTICROBIAL AGENTS AND THEIR USES
JP2000532142A JP4470007B2 (en) 1998-02-20 1999-02-19 Method for selecting tumors that express HLA-G and are sensitive to anti-cancer therapy and uses thereof
US09/622,583 US6790638B1 (en) 1998-02-20 1999-02-19 Method for selecting tumours expressing HLA-G, sensitive to anticancer treatment and uses
PCT/FR1999/000386 WO1999042128A1 (en) 1998-02-20 1999-02-19 Method for selecting tumours expressing hla-g, sensitive to anticancer treatment and uses
US10/788,374 US20040209296A1 (en) 1998-02-20 2004-03-01 Method for selecting tumours expressing HLA-G which are sensitive to anticancer treatment, and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9809470A FR2775189B1 (en) 1998-07-24 1998-07-24 ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES

Publications (2)

Publication Number Publication Date
FR2775189A1 FR2775189A1 (en) 1999-08-27
FR2775189B1 true FR2775189B1 (en) 2001-06-08

Family

ID=9528977

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9809470A Expired - Fee Related FR2775189B1 (en) 1998-02-20 1998-07-24 ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES

Country Status (1)

Country Link
FR (1) FR2775189B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11827708B2 (en) 2020-07-29 2023-11-28 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05246889A (en) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk Carcinostatic method and carcinostatic agent
FR2717498B1 (en) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcripts of the HLA-G class I MHC gene and their applications.
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use

Also Published As

Publication number Publication date
FR2775189A1 (en) 1999-08-27

Similar Documents

Publication Publication Date Title
FI972945A (en) Compositions suitable for the administration of antigens
IS5375A (en) KAY-Innovative Immune Protein
FI20115005A (en) Melanoma antigen
FI964235A (en) Melanoma antigen
IT1302059B1 (en) ANALYSIS DEVICE.
DE69529288D1 (en) WATER-SOLUBLE POLYEN CONJUGATES
DE69608823D1 (en) Mail merge
LV11630A (en) T-dog antigen receptor V region full length proteins
DE69403209D1 (en) Sintered self-reinforced silicon nitride
OA08477A (en) Multiple protection human monoclonal antibody compositions.
NO993694L (en) Sylphonylurea and adjuvant based solid compositions
DE69026492D1 (en) Silicon nitride body
FR2775189B1 (en) ANTI-TUMOR COMPOSITIONS BASED ON HLA-G ANTIGENS OR ANTI-HLA-G ANTIBODIES
DE69828937D1 (en) Piece d'interposition
FR2759747B1 (en) STAPLING CLIP
EP0485476A4 (en) Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
IT1292163B1 (en) IMMUNOCROMATOGRAPHIC DEVICE FOR FIXING THE ANALYT
DE59307850D1 (en) Si / SiGe BARITT diode
DE69503248D1 (en) SINDERED REACTION-RELATED SILICON NITRIDE COMPONENTS
DE69632558D1 (en) Polyphthalamide resin compositions
FR2757862B1 (en) ANTIGENIC PEPTIDES REACTING WITH ANTI-OVARY ANTIBODIES
KR970049692U (en) Bib height adjuster
SE9802270D0 (en) Novel car antigen 3
MA26665A1 (en) COMBINATION OF ANTIBODIES
SE9002479D0 (en) ANTIBODY CONJUGATES

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20081031